Introduction
Defects in apoptotic signaling are central to tumor initiation and maintenance of cancer cells, particularly when associated with unregulated tumor cell proliferation. [1] [2] [3] [4] Amplification of the gene encoding the anti-apoptotic protein Myeloid cell leukemia-1 (Mcl-1) is one of the most common genetic aberrations in human cancer. 5 Mcl-1 over expression in human cancers is associated with high tumor grade and poor survival. 6 This suggests that inhibition of Mcl-1 could cause tumor cell death in Mcl-1-dependent cancers and cause an increase in sensitivity to many standard chemotherapeutics by releasing apoptotic restrictions.
Mcl-1 mediates its effects primarily through a protein-protein interaction and is difficult to target with small molecules. 7 Recently, we reported on ligands that bind tightly to Mcl-1 that are lipophilic and contain an acidic functionality. [8] [9] [10] [11] Although these molecules bind tightly to Mcl-1, they also bind to albumin as suggested by their lower in vitro cell activity in the presence of 10% FBS and no measurable in vitro free fraction. To improve our series' in vitro cell activity, we wanted to design Mcl-1 inhibitors with reduced binding to albumin. This was accomplished in the past when targeting the Bcl-2 family members Bcl-xl/Bcl-2 using a structure-based approach. 12 By comparing ligand binding to HSA and Bcl-xl, Bcl-2 family inhibitors were designed with a significant decrease in albumin binding. A similar approach was used for inhibitors of Methionine aminopeptidase-2 (MetAP2) which led to compounds with good cellular activity in both proliferation and methionine processing assays. 13 Many other studies have monitored ligand binding to plasma proteins to discover small molecules with reduced albumin binding. 14 For example, in the discovery of a series of DPP-IV inhibitors, a correlation between in vitro potency, plasma concentration and free fraction was observed 15 that was used to guide inhibitor design. 
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Bioorganic & Medicinal Chemistry j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / b m c site near domain IB of albumin. 17 Larger, rigid, and extended, higher molecular weight ligands typically bind to a third site in domain IB. All three sites share common physical characteristics; a hydrophobic pocket near multiple basic residues, which helps explain the protein's broad tolerance for a diverse group of lipophilic ligands which contain an acidic moiety. Several compounds have been found that bind to site 3 of albumin. 16 However, the number of molecules that have been structurally characterized is much lower than to site 1 or 2 making further structural characterization of ligand binding to this site of broad interest. Additional structural data for this site would provide additional data to optimize QSAR models and for docking approaches to predict albumin binding of compounds. [18] [19] [20] Here we report on the X-ray structure of an Mcl-1 inhibitor when bound to Human Serum Albumin in an effort to understand how to reduce HSA interference for this class of compounds. We were surprised to find that this Mcl-1 inhibitor binds predominantly to HSA site 3. When we compared our structure to other ligands that bind to the same pocket, we observed common binding hot spots and interactions that stabilize complex formation. The structure of this ligand when bound to HSA is consistent with the SAR we obtained on the plasma binding of other members of this chemical series. These data may thus be used to help design new analogs with reduced HSA binding without affecting binding to Mcl-1.
Experimental

Chemistry
Preparation of compound 1 (Fig. 1 ) was described previously. 11 
Purification of Human Serum Albumin
Albumin from human serum lyophilized powder and albumin human recombinant were purchased from Sigma-Aldrich. The protein was further purified by gel-filtration using S75 column chromatography.
HSA ligand free crystals were grown by sitting-drop vapor diffusion using a protein concentration of 100 mg/ml in 50 mM potassium phosphate (pH 7). The HSA compound 1 complexes were generated by soaking the ligand free crystals in mother liquor containing 2 mM compound 1 with 5% DMSO overnight.
X-ray crystallography
Data were collected on the Life Sciences Collaborative Access Team (LS-CAT) 21-ID-D beamline at the Advanced Photon Source (APS), Argonne National Laboratory. The data were indexed, integrated and scaled with HKL2000. Using a previously determined HSA ligand free structure (PDB: 4K2C) as a starting model, phasing was done by molecular replacement 21 with Phaser 22 as implemented in CCP4. Refinement of the structural models were performed with Phenix, and included rounds of manual model building in COOT. 23 The complex was refined to resolution of 2.7 Å. The final model has Rwork/Rfree 0.17/0.21 and good stereochemistry ( Table 2 Supplementary).
Graphics software
All figures were produced using the PyMOL Molecular Graphics System, version 1.7 (Schrödinger, LLC: New York, 2010).
Expression and purification of Mcl-1
Mcl-1 (172-318), corresponding to the N-terminal portion of Mcl-1, with an MBP tag was used for the TR-FRET biochemical assays. The design, characterization and sequence of this construct have been described earlier. 8 Soluble protein was purified by Ni affinity chromatography.
Caspase activation assay
NCI-H929 cells were washed twice in RPMI 1640 without Fetal Bovine Serum (FBS), then dispensed in 96 well plates at 10,000 cells per mL in RPMI 1640 containing 0.05% Pluronic F-68 nonionic surfactant (Thermo Fisher Scientific, Waltham MA) and 0, 1 or 10% FBS in white 96 well plates. Compound dose response curves were generated and added to the cells in their respective media. Plates are incubated with compound for 3 h then Caspase-Glo (Promega, USA) reagent is added and incubated at room temperature in the dark, for 30 min. Luminescence is measured on a BioTek Cytation 3 (Winooski VT, USA) and the IC 50 was determined using Graphpad Prism software (San Diego, CA). 15 .48 mM dibasic potassium phosphate, 1 mM sodium EDTA, 0.05% Pluronic F-68 detergent, 50 mM sodium chloride, and 1 mM DTT (pH 7.5). Compounds were added to the reaction mixture in DMSO. The final DMSO concentration was 0.25%. TR-FRET measurements were determined using a Biotek 3 multimode plate reader (Winooski VT, USA) at an excitation wavelength of 340 ± 30 nm, and dual excitation wavelengths of 520 ± 10 nm and 620 ± 10 nm. Delta F was determined by dividing the fluorescence at 520 nm by the fluorescence at 620 nm.
TR-FRET binding experiments
On each plate, wells containing the fluorescent peptide, Mcl-1-MBP protein, Terbium conjugated antibody, and vehicle (DMSO) served as a negative control. Wells containing peptide and antibody, in the absence of Mcl-1 protein served as a positive control for total displacement of peptide. For each compound, a dose response curve was generated by potting delta F values against compound concentration and the IC 50 was determined using a four parameter logistic curve fit with Graphpad Prism software. The dissociation constant (K i value) was derived from 24 :
where [I] 50 is the concentration of the free inhibitor at 50% inhibition, [L] 50 is the concentration of the free labeled ligand at 50% inhibition, [P] 0 is the concentration of the free protein at 0% inhibition, K d represents the dissociation constant of the FITC peptide probe. Experiments which determined the effect of albumin or bovine serum were performed in the same manner in assay buffer containing FBS, BSA, or HSA at the indicated concentration.
Results and discussion
Shift in activity due to albumin/serum binding
Compound binding to serum proteins can cause shifts in biochemical and in vitro cell assays making interpretation of structure activity relationships (SAR) complicated. 15, 18, 20, 25, 26 To test the effect of adding Fetal Bovine Serum (FBS) or albumin on the apparent compound activity of compound 1, we performed a plasma shift assay. The plasma shift assay is a common method to ascertain interference from FBS by adding serum to an in vitro assay and then observing a change in the apparent affinity to the target due to compound sequestration by plasma proteins. 12, 13, 15, 25 The plasma shift assay can be quantified to help monitor changes to compound binding to plasma proteins such as albumin. 25, 27 Quantification can be useful (Supplementary Materials) but in most cases the fold shift in the presence and absence of albumin is all that is used to compare compounds in the same chemical series.
12,15
For compound 1 in the TR-FRET competition assay, we observed a shift in IC 50 and apparent K i for binding to the target, Mcl-1, of over 3-fold between no FBS and 1% FBS (Fig. 2A) . When we repeated this experiment using delipidated HSA or BSA at the approximate concentration of albumin found in FBS (i.e. from FBS suppliers analysis 1% FBS corresponds to 180 lg/ml BSA), and we found a nearly identical shift in apparent K i (Table 1 ). This result is consistent with albumin being the major component in FBS that sequesters compound 1 and causes the right shift in the IC 50 in the binding assay. We next tested what effect different amounts of FBS had on compound 1 in an in vitro cell based activity assay.
To test the effect of FBS on in vitro cell based activity, we used a caspase activation assay. Rapid caspase activation is a characteristic of on target Bcl-2 family inhibitors [28] [29] [30] [31] and for compound 1, we see robust caspase activation in less than 3 h after dosing. We found that cells are more tolerant to different amounts of FBS in the caspase assay with a readout at 3 h, than in a 24 or 72 h proliferation assay. However, we still carefully normalized all of the data using DMSO as a control to reduce differences in capase activity due to changes in cell viability and changing serum conditions. As shown in Fig. 2B when we dosed cells with different amount of FBS, we observed more than a fifty fold shift in EC 50 in the caspase activation assay between 0% and 10% FBS. The pronounced shift in EC 50 in this cell based assay is similar to the effect we observed in the biochemical binding assay ( Fig. 2A) and is consistent with the hypothesis that compound binding to serum proteins is what causes an increase in the EC 50 needed to see a response in the cell based caspase activation assay. This experimental data demonstrates that serum protein binding is an important factor Based on the manufacturers analysis, the concentration of albumin in the lot used for these studies is 180 lg/ml at 1% FBS. to consider in interpreting our compound SAR in cell based assays containing serum.
Structures of compounds binding to site 3 of Human Serum Albumin
To help understand the structural basis for binding to albumin, we determined the structure of 1 bound to HSA. The three dimensional structure of compound 1 bound to Human Serum Albumin was obtained by X-ray crystallography. From the structure of compound 1 complexed to HSA (Fig. 3A) , we observed that this compound binds to site 3 in domain IB (Fig. 3B) . Some additional, but small volumes of unaccounted-for electron density (at the 3 sigma level) are present in site 2. The residual density was however poorly defined and a model for the ligand could not be built in this density. There are two HSA molecules in the asymmetric unit, and the electron density of the inhibitor in site 3 is present in both copies with a ligand occupancy in each copy of about 0.8.
The site 3 binding pocket in domain IB of albumin is formed by four alpha helices and is covered by an extended loop (Fig. 3A,B) . The pocket consists of a mix of hydrophobic and polar residues, which enables it to recognize fatty acids as well as bilirubin and other larger acid containing lipophilic molecules. Compound 1 contains three parts ( Fig. 1) with different physical characteristics. The propyl linker and dimethyl chloro phenyl (region A in Fig. 1 ) is the most hydrophobic and flexible part of the ligand and it packs against complementary hydrophobic residues of albumin near to residue I142. The top of the ligand containing the trimethyl pyrazole (region B) is a balance of polar hydrophilic and hydrophobic moieties. This region of the ligand is covered by loop L1 (115-118) of albumin. The hydrophobic loop residues, L115 and P118 sit above the ligand in the pocket, and the guanidine of R117 makes both polar and hydrophobic contacts with compound 1. Most of the pyrazole at the 7 position of the indole packs tightly against albumin with the exception of the 1 position at the top of the pyrazole which is partially exposed to solvent. The 6-Cl indole core sits in a more polar region of the pocket and is near to K137, Y161, and Y138. Finally, the indole acid headpiece (region C) is the most exposed part of the molecule when bound to albumin. The acid of the indole headpiece sits near R186 and R117 with most of the indole headpiece sitting at the edge of the cleft between domains IB and IIIB. The Arg residues near the ligand in the structure suggests that removal of the acid or changing its position could change the albumin binding affinity of the ligand.
In Fig. 3 (C,D) , we compare the binding of our ligand to two other compounds that bind to site 3, Bilirubin (Fig. 3C , PDB ID: 2VUE 32 ) and Camptothecin (Fig. 3D , Pdb ID: 4L9K 17 ). Although very different in their physical characteristics, all of the ligands share common binding interactions. In the bilirubin (cyan) structure, the 3-methyl-4-vinyl-dihydro-pyrrol-2-one, binds into the same hydrophobic pocket near I142 as the dimethyl chloro phenyl of our Mcl-1 inhibitor. Bilirubin's other 3-methyl-4-vinyl-dihydropyrrol-2-one overlaps with the 7-pyrazole of our ligand. The two acids of bilirubin interact with R186 and R117. Similar contacts are made by camptothecin. In camptothecin, the quinolone of the pentacyclic ring sits near residue I142 making a hydrophobic contact analogous to the dimethyl chloro phenyl of compound 1 and the 3-methyl-4-vinyl-dihydro-pyrrol-2-one of bilirubin. The hydroxyl and acid of camptothecin makes polar contacts to both R186 and R117 in a similar fashion as bilirubin and compound 1.
The binding motif of these three ligands share 2 common interactions with albumin. The first is hydrophobic burial of the ligand in the pocket around I142, which may serve as the hydrophobic hotspot that anchors ligands to Site 3. The second interaction, involves a polar contact to R186 and/or R117 which is also likely to be a common contact exploited by ligands that bind to site 3.
Species differences in binding site 3 of albumin
Rodent PK studies are generally used to help predict the PK in humans. 33 Differences in albumin from different species can however change drug binding in plasma and hence the PK in rodents versus humans. 17 We used a sequence alignment (Supplementary   Material Table 3 ) between rodent and human albumin to compare the differences in the albumin binding sites. It can be seen from this alignment that the ligand contact residues in drug binding site 1 and 2 are mostly conserved. However, site 3 has two residues that are different in rodents and humans, R186K and I142V, both of which contact compound 1. These are conservative differences and when we tested our compound using albumin from rat serum and human albumin both at 200 lg/ml, we saw no significant difference in the plasma shift assay (data not shown).
Comparison to ligand binding to Mcl-1
Many of the features of compound 1 that contribute to binding to albumin are also important for binding to Mcl-1. If the ligand structure of 4A is used to superimpose the Mcl-1 complex onto the albumin complex by using a pairwise fit of all ligand and no protein atoms, the superposition shown in Fig. 4B is obtained. In both complexes, the di-methyl chloro phenyl of the ligand pushes deep into a hydrophobic pocket. In Mcl-1, this pocket is formed by helix 4 and 5 while in HSA the pocket is formed by helix 9 and 10 of site 3 domain IB. The propyl-di-methyl chloro phenyl of the ligand is flexible and adapts different binding poses in the hydrophobic pocket of Mcl-1 and HSA Site 3. The indole acid is also rotated in the HSA structure when compared to its pose in Mcl-1 (Fig. 4B ). This suggests that reducing the rotation of the headpiece could also decrease ligand binding to HSA.
In Fig. 4C ,D, three areas of the ligand are evident that could potentially be used to create a steric hindrance to albumin binding. These are substitutions in the headpiece, lactam bridge or on the pyrazole of the ligand. We show in the Supplementary Material, earlier data on ligands with larger substitutions on the pyrazole. The improvement in plasma shift observed in these earlier compounds is consistent with our structural analysis of compound 1 binding to albumin.
Conclusion
We observed that the cell efficacy of compound 1 was reduced in in vitro binding and cell based assays in the presence of FBS or albumin. In order to help understand the structural basis of this interference, we determined the structure of compound 1 when bound to albumin and found that it binds to site 3 in domain IB. Site 3 is likely better suited to accommodate our compound because it is larger than the pockets in drug sites 1 and 2. The structure of compound 1 with HSA and with Mcl-1 was compared to identify the common and different binding features of the ligand to each individual protein. Even though HSA can adapt to many different ligands, a structural analysis can generally identify regions of the ligand that can be modified to reduce albumin binding and still maintain or improve binding to target. 12, 13 For our compound, we observed three potential regions that could be modified to reduce albumin binding while maintaining binding to Mcl-1. Ligands binding to drug site 3 of HSA may be more common for larger more extended molecules. The structural data presented here adds to the knowledge base of preferences for this site and could be useful for the development of QSAR models and docking approaches to predict albumin binding of compounds to this site. 18, 19 
